Healthy lifestyle, metabolomics and incident type 2 diabetes in a population-based cohort from Spain

Mario Delgado-Velandia1, Vannina Gonzalez-Marrachelli2,3, Arce Domingo-Rellos4,5,6, Marta Galvez-Fernandez1,4, Maria Grau-Perez1,3,6, Pablo Olmedo3,7, Iñaki Galan1,8, Fernando Rodriguez-Artalejo1,9,10, Nuria Amigo11,12,13, Laisa Briongos-Figuero14, Josep Redon3, Juan Carlos Martin-Escudero14, Daniel Monleon-Salvado2,3,15,16*, Maria Tellez-Plaza1,3,4,8*,† and Mercedes Sotos-Prieto1,9,10,17†

Abstract

Background: The contribution of metabolomic factors to the association of healthy lifestyle with type 2 diabetes risk is unknown. We assessed the association of a composite measure of lifestyle with plasma metabolite profiles and incident type 2 diabetes, and whether relevant metabolites can explain the prospective association between healthy lifestyle and incident type 2 diabetes.

Methods: A Healthy Lifestyle Score (HLS) (5-point scale including diet, physical activity, smoking status, alcohol consumption and BMI) was estimated in 1016 Hortega Study participants, who had targeted plasma metabolomic determinations at baseline examination in 2001–2003, and were followed-up to 2015 to ascertain incident type 2 diabetes.

Results: The HLS was cross-sectionally associated with 32 (out of 49) plasma metabolites (2.5% false discovery rate). In the subset of 830 participants without prevalent type 2 diabetes, the rate ratio (RR) and rate difference (RD) of incident type 2 diabetes (n cases = 51) per one-point increase in HLS was, respectively, 0.69 (95% CI, 0.51, 0.93), and −8.23 (95% CI, −16.34, −0.13)/10,000 person-years. In single-metabolite models, most of the HLS-related metabolites were prospectively associated with incident type 2 diabetes. In probit Bayesian Kernel Machine Regression, these prospective associations were mostly driven by medium HDL particle concentration and phenylpropionate, followed by small LDL particle concentration, which jointly accounted for ~50% of the HLS-related decrease in incident type 2 diabetes.

Conclusions: The HLS showed a strong inverse association with incident type 2 diabetes, which was largely explained by plasma metabolites measured years before the clinical diagnosis.

Keywords: Cohort study, Healthy lifestyle, Metabolomics, Spanish population, Type 2 diabetes

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
explained less than ~15% of the type 2 diabetes heritability, it is suspected that the environment and lifestyle have a more relevant role in type 2 diabetes development [2]. Diet, physical activity, body mass index (BMI), smoking and alcohol consumption have been individually associated with increased type 2 diabetes risk [3]. Previous studies jointly evaluating multiple healthy lifestyle behaviours found greater reductions in type 2 diabetes risk compared to the expected reduction from the individual lifestyle factors [4, 5].

Metabolomics—the determination of intermediary molecules and metabolism by-products [6]— offer opportunities to understand biological pathways that are potentially influenced by lifestyles and can help identifying strategies for type 2 diabetes precision prevention [7]. Several lifestyle factors have been associated with individual metabolic markers [8, 9]. Alternatively, individual metabolites have been associated with different stages in the type 2 diabetes progression [8, 10]. For instance, in a meta-analysis of 19 prospective studies, specific branched chain and aromatic amino acids were associated with both pre-diabetes and type 2 diabetes [10]. Furthermore, some of the metabolites associated to type 2 diabetes have also been related to specific lifestyle factors -glutamine for alcohol consumption [11], and branch-chain amino acids for physical activity [12] and obesity [13]. However, the contribution of metabolomic profiles to explain the association of a composite measure of overall lifestyle with type 2 diabetes risk is unknown.

Therefore, the aim of this study was to assess the association between adherence to a healthy lifestyle (measured by the Healthy Lifestyle Score [HLS]) with metabolic profiles and incident type 2 diabetes. In order to identify the most relevant metabolites in our data, we also used a probit extension of Bayesian Kernel Machine Regression (BKMR-P), which allowed to evaluate the prospective association of simultaneously-modelled metabolites with type 2 diabetes, as it can handle correlations and high-order interactions between metabolites mixtures [14, 15]. We subsequently evaluated whether HLS-related differences in relevant metabolites can explain the prospective association between healthy lifestyle and incident type 2 diabetes after a 14-year follow-up.

**Methods**

**Study Participants**
The Hortega Study is a population-based cohort representative of a general population from Valladolid, Spain [16]. Details of the study design and data collection methods have been described elsewhere [16]. The study population consisted of 1502 beneficiaries of the universal public health system assigned to the University Hospital Rio Hortega (UHRH) catchment area. Baseline physical examination (2001–2003) included validated questionnaires and laboratory assessment of standard biochemical profiles, and collection of plasma samples for metabolomics. In 2015, two physician reviewers blindly assessed the participants’ medical records and adjudicated health events that occurred during follow-up. The study protocol was approved by the institutional review board at UHRH and written informed consent was obtained from all participants [16].

Out of the 1502 recruited individuals, we sequentially excluded participants missing information on metabolomics (n=299), smoking status (n=2), educational level (n=3), BMI (n=40), diet (n=141), and leisure time physical activity (n=1) leaving 1016 participants for the cross-sectional analysis. The participant characteristics comparing excluded and included participants were similar (Supplementary Table S1, Additional File 1). We additionally excluded participants with prevalent type 2 diabetes at baseline (n=94) and participants lost to follow-up (n=92), leaving 830 participants for the prospective analyses of lifestyle-related metabolites and incident type 2 diabetes (See Supplementary Fig. S1, Additional File 1).

**Type 2 Diabetes assessment**

Blood samples were collected after a mean fasting time of 3 h (range 0–17 h). Glycaemia was determined through the glucose oxidase method using a Hitachi 704 analyzer (Boehringer Mannheim, Germany). Participants with non-fasting glucose levels ≥7.8 mmol/l underwent second fasting glucose and glycosylated hemoglobin (HbA1c) determinations. HbA1c was measured from capillary blood samples using a DCA 2000 HbA1c analyzer (Bayer Diagnostics, Tarrytown, NY, USA). Participants were considered as prevalent type 2 diabetes cases if they had medical diagnosis before the baseline examination or there were records of diabetes medication use on their medical history; or if their baseline fasting plasma glucose was ≥7.0 mmol/l or HbA1c was ≥48 mmol/mol (≥6.5%). Participants were considered as incident type 2 diabetes cases if they were diabetes-free at baseline examination and the diagnosis of type 2 diabetes on their medical record met the diabetes definition during follow-up [16]. The validity of electronical medical records for the ascertainment of type 2 diabetes in the context of epidemiological studies within the Spanish universal public health system has been evaluated before [17]. In a subsample of public health system beneficiaries from Madrid [17], electronic health records showed adequate positive and negative predictive values (87.9 and 97.3%, respectively) for the identification of type 2 diabetes.
Healthy Lifestyle Score
The Healthy Lifestyle Score (HLS) was estimated at baseline and included five-components (diet, physical activity, smoking status, alcohol consumption and BMI), following a well-established approach [18]. Scores for each component were 0 points (non-adherence) or 1 point (adherence) with a total range of 0–5 points, with a higher score indicating higher adherence to a healthy lifestyle. All women and men had daily energy intakes ranging 2092 to 14,644 kJ/day (500 to 3500 kcal/day), and 3347.2 and 16,736 kJ/day (800 to 4000 kcal/day), respectively. The alternate Mediterranean Diet score (aMED) measured the degree of adherence to a Mediterranean diet [19], instead of the Alternate Healthy Eating Index (AHEI) [18], since the aMED score is more appropriate to our study population. The aMED score was derived by excluding the alcohol consumption item because it was already a component of the HLS. As a result, the aMED score ranged 0–8 points. Healthy diet (1 point) was defined as an aMED score in the top 40% of the distribution (aMED ≥ 5). Women with alcohol intakes between 5 and 15 g/day and men with alcohol intakes between 5 and 30 g/day were given 1 point; all other participants received none [18]. Leisure-time physical activity was assessed as type of sports practiced and amount of time practicing each sport per week. The METs-minute/week (Metabolic Equivalent of Task-minute/week) were calculated using the equivalences in the Compendium of Physical Activities 2011 [20]. Participants received 1 point if they achieved at least 600 METs-minute/week performing moderate or vigorous leisure time physical activities, as recommended by the World Health Organization [21]. The BMI was derived from height and weight measured in standardized conditions; a BMI 18.5–24.9 kg/m² was considered as healthy (1 point). Participants self-identified as never smokers were awarded 1 point; former and current smokers received none. Finally, we categorized the HLS in low (0–1 points), medium (2 points), and high adherence (3–5 points) groups.

Metabolites Assessment
Metabolites levels were measured at baseline through nuclear magnetic resonance (NMR) using a Bruker Avance DRX 600 spectrometer (Bruker GmbH, Germany). The chemical shift region studied was between 0.50–4.70 ppm (ppm). The obtained spectra were normalized to total aliphatic spectral area after being binned into buckets of 0.01 ppm. The signals of the targeted metabolites were processed using in-house routines for MATLAB V.6.5. The results were confirmed through superposition of normalized serum spectra derived from two-dimensional NMR methods, namely homonuclear correlation spectroscopy and heteronuclear single quantum correlation spectroscopy. An extended lipoprotein profile was evaluated using the LIPOSCALE® method for NMR spectra [22, 23], and included lipoprotein lipid composition and size of the three main classes (VLDL, LDL and HDL) and the particle concentration of their respective subclasses (large, medium, and small). Particle concentrations and lipoprotein subtypes were determined using the distinctive signals of the lipid methyl group. Lipid concentration were converted to lipid volumes using common conversion factors [23]. The available set of metabolites to conduct the study objectives included 12 amino acids, 6 fatty acids, 5 products of bacterial co-metabolism, 17 lipoprotein subclasses, the sphingolipid-related O-phosphoethanolamine, 2 fluid balance and 6 energy metabolism-related metabolites. We adjusted all metabolites measures to the number of fasting hours at the time of plasma sample collection using linear regression and recalibrated the resulting residuals to the mean metabolite concentrations in the study population.

Other variables
Information on education was self-reported. Prevalent dyslipidemia was defined as either lipid-lowering medication use recorded on medical history or as a non-fasting total cholesterol > 5.2 mmol/l. Prevalent hypertension was defined as systolic/diastolic blood pressure (average between two measurements with a 5-min interval assessed by trained personal) > 140/90 mmHg; or a medical record with prior hypertension diagnosis or blood pressure-lowering medication use.

Statistical analysis
Descriptive analysis and association of HLS with metabolites
In order to account for the complex sampling design and survey weights, we conducted the statistical analyses using the “survey” package in R software (version 4.0.2, R Core Team 2020). We summarized the participants’ characteristics using descriptive statistics (mean and proportions). We descriptively estimated the survey-weighted type 2 diabetes incidence rate by using generalized linear models as conducted with the svyglm() command from the R survey package with family Poisson and link log, which included an offset term for the individual log-transformed person-years of follow-up and no covariates. For metabolic data, we calculated median and interquartile range by HLS categories. In non-exploratory analysis, the type 1 error probability threshold was generally set to 0.05 (two tailed). However, the cross-sectional evaluation of adherence to the HLS with individual metabolites in separate linear regression models, was exploratory. In order to account for multiple exploratory testing in this
context, we set a false discovery rate (FDR) significance threshold of 2.5% as conducted by the R package “qvalue” [24], with a lambda parameter set to 0. We conducted two progressively adjusted models: Model 1 adjusted for age (years), sex (male, female) and education (≤ high school, > high school); and Model 2 included Model 1 and prevalent hypertension (no, yes), total plasma cholesterol (mg/dL) and use of lipid-lowering medication (no, yes).

**Association of HLS and incident type 2 diabetes**

We estimated adjusted rate ratios (RR) and rate differences (RD) per 10,000 person-years of incident type 2 diabetes, by adherence to the baseline HLS (categorized and continuous) using Poisson and Aalen additive hazards models, respectively. Given the controversial evidence on the protective effect of alcohol consumption on type 2 diabetes risk [25], we conducted sensitivity analysis: a) including alcohol in both aMED [19] and HLS scores definition; b) excluding alcohol from both aMED and HLS scores definition; c) with non-drinkers being also awarded 1 point in the alcohol consumption component of HLS. In secondary analyses, we examined the associations of HLS and type 2 diabetes by subgroups defined by sex, education, and prevalent dyslipidemia and hypertension status introducing interaction terms in the regression models.

**Association of metabolites with incident type 2 diabetes**

First, we estimated fully adjusted rate ratios (RR) and rate differences (RD) of incident type 2 diabetes by individual HLS-related metabolites using Poisson and Aalen additive hazard models, respectively. We re-scaled the resulting coefficients and confidence intervals to compare the 90th to the 10th percentiles of each metabolite distribution in order to improve their interpretability. Second, we used BKMR to simultaneously evaluate the association of these metabolites with incident type 2 diabetes [15]. BKMR uses a flexible kernel to handle high dimensional correlations, to account for non-linearity and to provide an estimation of both individual and joint effect of compounds mixtures [15]. The R package BKMR conducts Bayesian inference for the probit regression model (BKMR-P), which we adapted to time-to-event survey data using a data augmentation approach [14]. The posterior inclusion probabilities (PIP) (from 0 to 1) obtained from the BKMR-P quantify how much the data favors the inclusion of a metabolite in the model.

Subsequently, to evaluate whether relevant metabolites contribute to explain the association of HLS and type 2 diabetes, we estimated the amount of avoided incident type 2 diabetes cases per 1-point HLS increase (per 10,000 person-years) that can be attributed to differences in metabolites levels, estimated as the relative change in the beta coefficient associated to HLS from the Aalen additive hazard models when each metabolite group was introduced in the model (i.e. the relative amount of association explained by metabolites was estimated as [1 − (difference in type 2 diabetes rates per one HLS point increase in models adjusting for specific metabolites group / difference in type 2 diabetes rates per one HLS point increase in the reference model without metabolites)] × 100). Additive hazard models are recommended to study the contribution of intermediate variables in survival settings [26].

In confirmatory post-hoc analysis, we used formal causal mediation analysis for survival outcomes [26, 27], to evaluate whether the sum of estimated relative mediated effects for the most relevant individual metabolites did equal the percent explained in the association of HLS and incident diabetes with and without relevant metabolites entered as a group (as expected when the causal mediation assumptions hold, and the individual metabolites are not causally correlated). In particular we used the product of coefficients method to calculate natural indirect effects. The Aalen additive hazards outcome model included time to incident diabetes as the outcome, HLS as the exposure and most relevant metabolites (i.e., those identified by the BKMR analysis) as mediators. The mediator models were linear models where each relevant metabolite was entered as the dependent variable in separate mediator models and HLS (exposure) was entered as the independent variable. Both outcome and mediator models were adjusted for age, sex, education, prevalent hypertension, total plasma cholesterol, use of lipid-lowering medication and the other relevant metabolites. As result, absolute mediated effects (natural indirect effects) were also reported as the number of avoided incident type 2 diabetes cases per 1 HLS-point increase (per 10,000 person-years) that can be independently attributed to differences in specific metabolites levels after accounting for other relevant metabolites. The relative mediated effect was calculated as the ratio between mediated effects and adjusted changes in diabetes cases per 1 HLS-point increase before adding the specific metabolite to the model. Confidence intervals were calculated using a resampling method that takes random values from multivariate normal distribution of the estimates [26, 27].

**Results**

**Descriptive analysis**

In our study population the mean age was 48.5 years and 49% of participants were males (Table 1). Participants with higher adherence to the HLS were more likely to be younger and female, with lower prevalence of dyslipidemia and hypertension (Table 1). The median HLS was
2 points. Never smoking was the HLS component for which the participants had the highest compliance with the recommendations, while alcohol consumption had the lowest (See Supplementary Table S2, Additional File 1). Lipoprotein composition and particle concentrations including VLDL, LDL and IDL cholesterol and triglycerides; large, medium and small VLDL, and small LDL, as well as, −CH₂N fatty acids and acetone concentrations progressively decreased across the HLS categories (See Supplementary Table S3, Additional File 1). Increasing HLS categories showed increasing concentrations of other metabolites such as amino acids, citrate, pyruvate, 3-hydroxybutyrate, isopropanol, trimethylamines or phenylpropionate (See Supplementary Table S3, Additional File 1). Increasements progressively decreased across the HLS categories of bacterial co-metabolism (n = 3) (MD were 0.09 [0.05, 0.14] for phenylpropionate; to 0.05 [0.03, 0.08] for isopropanol); and fluid balance (n = 2) (MD were 0.07 [0.03, 0.11] albumin; and 0.02 [0.01, 0.03] for creatinine).

Prospective association of HLS and type 2 diabetes
The number of incident type 2 diabetes cases after a median follow-up time of 13.3 years was 51 (the survey-weighted incidence rate during the study period was 40.2 per 10,000 person-years). The fully adjusted RR of diabetes comparing the medium and high (2 and 3–5 points, respectively) to the low (0–1 points) HLS adherence categories were 0.83 (95%CI 0.44, 1.56) and 0.20 (95%CI 0.04, 0.88), respectively (See Supplementary Table S5, Additional File 1); and their corresponding differences in incident rates were −7.15 (95%CI -34.31, 20.01) and −24.47 (95%CI -43.87, −5.06) (See Supplementary Table S6, Additional File 1). The corresponding estimates per 1 HLS point increase was 0.69 (95%CI 0.51, 0.93) for RR (See Supplementary Table S5, Additional File 1) and −8.23 (95%CI -16.34, -0.13) for RD (See Supplementary Table S6, Additional File 1). In sensitivity analysis, similar results were obtained when alcohol consumption was included in both aMED and HLS, when alcohol consumption was excluded from both aMED and HLS, and when non-drinkers were awarded 1 point in the alcohol consumption component of the HLS (See Supplementary Table S7, Additional File 1). We did not observe differential associations by subgroups (See Supplementary Table S8, Additional File 1).

Cross-sectional association of HLS and metabolites
At a FDR of 2.5% HLS was associated with 32 out of 49 plasma metabolites (Table 2). The most frequently associated metabolites were the lipoprotein particles subclasses and content group (n = 10) (mean difference [MD] [95% CI] ranged from −19.43 [−29.00, −9.87] nmol/l for small LDL to −0.005 [−0.01, −0.002] mmol/l for IDL triglycerides); followed by the amino acids group (n = 8) (MD [95% CI] ranged from 0.11 [0.06, 0.17] for alanine, to 0.01 [0.004, 0.02] for cysteine); the energy metabolism group (n = 5) (MD ranged from −0.10 [−0.16, −0.05] for acetone; to 0.02 [0.01, 0.03] for pyruvate); products

| Table 1 | Participants characteristics by Healthy Lifestyle Score categories in the Hortega Study (n = 1016) |
|---------|--------------------------------------------------------------------------------------------------|
|         | Overall | Low HLS (0–1 points) | Moderate HLS (2 points) | High HLS (3–5 points) |
| n (%)   | 1016    | 491 (46.41)          | 310 (30.39)            | 215 (23.20)           |
| Age, years, mean (SE) | 48.54 (17.07) | 51.41 (16.96) | 49.88 (16.67) | 41.03 (15.54) |
| Sex, Male, n (%) | 511 (48.96) | 280 (55.50) | 126 (39.87) | 105 (47.80) |
| Education, ≤High school, n (%) | 725 (68.99) | 374 (74.65) | 227 (70.55) | 124 (55.63) |
| Energy intake, Kilocalories/day, mean (SE) | 2235.80 (705.81) | 2193.93 (705.76) | 2236.69 (697.55) | 2318.41 (709.44) |
| Prevalent type 2 diabetes, Yes, n (%) | 94 (6.99) | 59 (8.98) | 30 (7.82) | 5 (1.94) |
| Prevalent dyslipidaemia, Yes, n (%) | 538 (51.74) | 291 (58.94) | 167 (52.92) | 80 (35.81) |
| Prevalent hypertension, Yes, n (%) | 441 (43.60) | 259 (51.42) | 131 (37.11) | 51 (19.83) |
| Healthy Lifestyle Score (HLS) components | | | | |
| BMI, kg/m², mean (SE) | 26.17 (4.18) | 27.44 (4.01) | 26.11 (4.41) | 23.72 (2.92) |
| Leisure time physical activity, METs-minute/week, mean (SE) | 463.57 (1280.05) | 149.13 (607.17) | 324.36 (770.99) | 1274.99 (2160.09) |
| 8-point aMED (alcohol excluded), mean (SE) | 3.70 (1.62) | 3.11 (1.30) | 4.06 (1.68) | 4.42 (1.70) |
| Alcohol intake, grams/day, mean (SE) | 11.81 (21.97) | 15.21 (28.80) | 7.93 (13.14) | 10.08 (12.20) |
| Smoking status, Never smoker, n (%) | 441 (43.60) | 259 (51.42) | 131 (37.11) | 51 (19.83) |

Abbreviations: BMI/BMI Body Mass Index; aMED alternate Mediterranean Diet score; HLS Healthy Lifestyle Score; MET Metabolic Equivalent of Task; SE standard error
| Group                      | Metabolite       | Model 1 | p-value | Model 2 | p-value |
|----------------------------|------------------|---------|---------|---------|---------|
| Lipoprotein profile        |                  |         |         |         |         |
| Cholesterol, mmol/l        |                  |         |         |         |         |
| VLDL cholesterol           | -0.07 (−0.09, -0.04) | <0.001 | -0.05 (−0.07, -0.03) | <0.001* |
| LDL cholesterol            | -0.11 (−0.17, -0.05) | <0.001 | -0.03 (−0.06, 0.002) | 0.04    |
| HDL cholesterol            | 0.04 (0.02, 0.07)  | 0.001   | 0.05 (0.02, 0.07)    | <0.001* |
| IDL cholesterol            | -0.02 (−0.03, -0.01) | <0.001 | -0.01 (−0.02, -0.003) | 0.006*  |
| Triglycerides, mmol/l      |                  |         |         |         |         |
| VLDL triglycerides         | -0.13 (−0.19, -0.08) | <0.001 | -0.1 (−0.14, -0.05)  | <0.001* |
| LDL triglycerides          | -0.007 (−0.01, -0.002) | 0.006 | -0.001 (−0.005, 0.002) | 0.43    |
| HDL triglycerides          | -0.003 (−0.01, 0.0007) | 0.11  | -0.002 (−0.01, 0.002) | 0.24    |
| IDL triglycerides          | -0.007 (−0.01, -0.04) | <0.001 | -0.005 (−0.01, -0.002) | 0.003*  |
| Lipoprotein particle concentration |            |         |         |         |         |
| Large VLDL, mmol/l         | -0.18 (−0.27, -0.09) | <0.001 | -0.13 (−0.21, -0.06) | <0.001* |
| Medium VLDL, mmol/l        | -1.13 (−1.64, -0.62) | <0.001 | -0.78 (−1.24, -0.33) | <0.001* |
| Small VLDL, mmol/l         | -7.34 (−10.21, -4.47) | <0.001 | -5.33 (−7.85, -2.80) | <0.001* |
| Large LDL, mmol/l          | -4.58 (−7.54, -1.63) | 0.002  | -0.98 (−2.79, 0.83)  | 0.29    |
| Medium LDL, mmol/l         | -10.11 (−19.62, -0.6) | 0.04   | 1.19 (−4.59, 6.97)   | 0.69    |
| Small LDL, mmol/L          | -35.75 (−50.87, -20.63) | <0.001 | -19.43 (−29.00, -9.87) | <0.001* |
| Large HDL, μmol/L          | 0.001 (−0.003, 0.01) | 0.68   | 0.003 (0.0002, 0.001) | 0.04    |
| Medium HDL, μmol/L         | 0.22 (0.06, 0.38)  | 0.008   | 0.24 (0.08, 0.4)     | 0.003*  |
| Small HDL μmol/L           | 0.25 (−0.08, 0.57) | 0.13   | 0.35 (0.02, 0.67)    | 0.04    |
| Amino acids b               |                  |         |         |         |         |
| Alanine                    | 0.14 (0.08, 0.20) | <0.001 | 0.11 (0.06, 0.17)    | <0.001* |
| Creatine phosphate         | 0.02 (0.01, 0.03) | <0.001 | 0.01 (0.002, 0.02)   | 0.001*  |
| Creatine                   | 0.02 (0.01, 0.03) | <0.001 | 0.01 (0.005, 0.02)   | <0.001* |
| Cysteine                   | 0.02 (0.01, 0.02) | <0.001 | 0.01 (0.004, 0.02)   | 0.002*  |
| Glutamine                  | 0.11 (0.07, 0.15) | <0.001 | 0.08 (0.04, 0.12)    | <0.001* |
| N-acetylglutamine          | 0.08 (0.05, 0.11) | <0.001 | 0.06 (0.03, 0.08)    | <0.001* |
| Proline                    | 0.12 (0.07, 0.16) | <0.001 | 0.09 (0.05, 0.12)    | <0.001* |
| Tryptophan                 | 0.03 (0.01, 0.06) | 0.02   | 0.02 (0.05)          | 0.06    |
| Tyrosine                   | 0.02 (0.01, 0.04) | 0.002  | 0.01 (0.02)          | 0.08    |
| Isoleucine                 | 0.05 (0.02, 0.08) | 0.003  | 0.04 (0.04, 0.07)    | 0.02    |
| Leucine                    | 0.05 (0.02, 0.08) | <0.001 | 0.04 (0.01, 0.07)    | 0.01*   |
| Valine                     | 0.05 (0.02, 0.09) | 0.003  | 0.04 (0.01, 0.08)    | 0.02    |
| Fatty acids b              |                  |         |         |         |         |
| CH2CH2CO                   | -0.19 (−0.29, -0.09) | <0.001 | -0.14 (−0.24, -0.04) | 0.006*  |
| CH2CH3                    | -0.13 (−0.24, -0.03) | 0.009  | -0.07 (−0.17, 0.03)  | 0.15    |
| CH2N                      | -3.17 (−4.44, -1.89) | <0.001 | -2.17 (−3.33, −1.00) | <0.001* |
| CH3                       | -0.38 (−0.61, -0.15) | 0.001  | -0.19 (−0.37, -0.003) | 0.05    |
| CH2CH2CH                  | -0.03 (−0.08, 0.03) | 0.33   | -0.003 (−0.05, 0.05) | 0.92    |
| Isobutyrate                | 0.04 (0.01, 0.07)  | 0.003  | 0.03 (0.01, 0.06)    | 0.01*   |
| Fluid balance b            |                  |         |         |         |         |
| Albumin                    | 0.11 (0.07, 0.16) | <0.001 | 0.07 (0.03, 0.11)    | <0.001* |
| Creatinine                 | 0.03 (0.01, 0.04) | <0.001 | 0.02 (0.01, 0.03)    | <0.001* |
| Energy metabolism b        |                  |         |         |         |         |
| Glycolysis                 |                  |         |         |         |         |
| Citrate                    | 0.07 (0.04, 0.09) | <0.001 | 0.05 (0.03, 0.07)    | <0.001* |
| Lactate                    | -0.34 (−0.6, -0.09) | 0.009  | -0.24 (−0.48, 0.01)  | 0.06    |
| Pyruvate                   | 0.03 (0.02, 0.04) | <0.001 | 0.02 (0.01, 0.03)    | <0.001* |
| Ketone bodies              |                  |         |         |         |         |
| Acetate                    | 0.05 (0.03, 0.07) | <0.001 | 0.03 (0.01, 0.05)    | 0.001*  |
| Acetone                    | -0.13 (−0.19, -0.08) | <0.001 | -0.10 (−0.16, -0.05) | <0.001* |
| 3-Hydroxybutyrate          | 0.11 (0.07, 0.15) | <0.001 | 0.08 (0.04, 0.12)    | <0.001* |
Association of metabolites and type 2 diabetes

All the HLS-related metabolites (together representing 7 metabolites’ groups), except IDL cholesterol and triglycerides and creatinine, were individually associated with incident type 2 diabetes. In Aalen additive hazard models, the greatest differences in incident type 2 diabetes rates (95%CI) comparing the 90th to the 10th percentiles of metabolite distributions were observed for small LDL in the lipoprotein particles subclasses and contents group (78.19 [16.82, 139.56]); for N-acetylglutamine in the amino acids group (−71.46 [−109.9, −33.01]); for acetone in the energy metabolism group (72.26 [29.49, 115.03]); for trimethylamines in the products of bacterial co-metabolism group (−68.58 [−112.14, −25.01]); and for albumin in the fluid balance group (−70.49 [−112.51, −24.78]) (Table 3). In Poisson regression models, the association of HLS-related metabolites with incident type 2 diabetes was statistically significant and directionally consistent compared to results from Aalen regression models (Table 3). In BKMR analysis, the overall metabolites mixture was significantly and inversely associated with the type 2 diabetes risk (See Supplementary Fig. S2, Additional File 1). Phenylpropionate and medium HDL particles, which consistently showed and inverse association with incident type 2 diabetes (See Supplementary Fig. S3, Additional File 1), followed by small LDL particles, which consistently showed a positive association with incident type 2 diabetes (See Supplementary Fig. S3, Additional File 1), displayed posterior inclusion probabilities (PIPs) higher than 20% (PIPs were 1, 1 and 0.23 respectively) (See Supplementary Table S9, Additional File 1).

Contribution of metabolites to HLS-related type 2 diabetes

In models adjusting for age, sex, hypertension status, total cholesterol and lipid-lowering medication, 1-point increase in HLS was associated with 8.23 avoided incident diabetes cases/10,000 person-years (95% CI, 6.34, 0.13) after a 14-year follow-up (Table 4). This decrease in type 2 diabetes incidence rates (RD) was substantially attenuated when HLS and diabetes-related metabolites were sequentially introduced by metabolite groups in the adjusted Aalen model. Metabolites from the lipoprotein profile caused the greatest attenuation in estimated number of avoided type 2 diabetes incidence cases with a 45.9% change in the HLS coefficient [RD changed from −8.23 (95% CI, −16.34, −0.13) to −4.45 (−12.65, 3.75) after lipoproteins subclasses adjustment], followed by amino acids, bacterial co-metabolism, energy, fluid balance, phosphoethanolamines and fatty acids metabolites (corresponding % change in the HLS-regression coefficient was 45.4, 38.0, 36.8, 25.6, 24.2, and 22.5 respectively) (Table 4). When most relevant metabolites (i.e. metabolites with a PIP greater than 20% in the BKMR analysis) were simultaneously introduced in the model, the corresponding attenuation in the HLS-regression coefficient was 52.5% (Table 4). In other words, differences in relevant plasma metabolite measured at baseline approximately explained ~4 out of the 8 avoided incident diabetes cases/10,000 person-years attributable to a 1-point increase HLS, adjusting for age, sex, educational level, total cholesterol and lipid-lowering medication. Results from confirmatory post-hoc causal mediation analysis were supportive of the analysis that evaluated the change in the HLS-diabetes association with and without relevant metabolites entered as a group because the sum of the relative mediated effects of phenylpropionate, medium HDL and small LDL particle concentrations

Table 2 (continued)

| Products of bacterial co-metabolism b | Model 1 | Model 2 |
|----------------------------------------|---------|---------|
| ethanol                                | −0.05 (−0.16, 0.06) | 0.39 | −0.06 (−0.16, 0.04) | 0.24 |
| isopropanol                            | 0.08 (0.05, 0.11) | <0.001 | 0.05 (0.03, 0.08) | <0.001* |
| methanol                               | 0.01 (0.002, 0.002) | 0.008 | 0.01 (−0.0001, 0.01) | 0.05 |
| trimethylamines                        | 0.09 (0.05, 0.12) | <0.001 | 0.06 (0.03, 0.09) | <0.001* |
| phenylpropionate                       | 0.11 (0.07, 0.16) | <0.001 | 0.09 (0.05, 0.14) | <0.001* |
| phosphoethanolamines                   | 0.07 (0.04, 0.10) | <0.001 | 0.04 (0.02, 0.07) | 0.002* |

Abbreviations: MD mean differences; CI confidence interval; HLS Healthy Lifestyle Score. * n = 1016
Model 1 was adjusted for age (years), sex (men, women) and education (≤ high school, > high school). Model 2 was model 1 additionally adjusted for prevalent hypertension (no, yes), total plasma cholesterol (mg/dL) and use of lipid lowering medication (no, yes).

b We normalized the spectral vector to the total spectral area excluding residual water signals to minimize the effects of variable dilution of the sample. The metabolic content is therefore expressed in relative metabolic content (unitless)

* Significant at a 2.5% False Discovery Rate
Table 3  Rate Ratio and Rate Difference per 10,000 person-years, for incident type 2 diabetes (95%CI) comparing the 90th to the 10th percentiles of HLS-related metabolites distributionsa

| Group               | Metabolite            | RR (95%CI) | p-value | RD (95%CI)   | p-value |
|---------------------|-----------------------|------------|---------|--------------|---------|
| Lipoprotein profile | Cholesterol           |            |         |              |         |
|                     | VLDL cholesterol      | 2.12 (1.45–3.08) | <0.001  | 2.09 (1.35–3.24) | <0.001  |
|                     | HDL cholesterol       | 0.21 (0.07–0.66) | 0.008   | 0.28 (0.10–0.79) | 0.02    |
|                     | IDL cholesterol       | 1.27 (0.75–2.15) | 0.38    | 1.11 (0.61–2.01) | 0.74    |
| Triglycerides       | VLDL triglycerides    | 2.07 (1.48–2.91) | <0.001  | 2.02 (1.38–2.95) | <0.001  |
|                     | IDL triglycerides     | 1.25 (0.69–2.29) | 0.46    | 1.14 (0.60–2.17) | 0.69    |
| Lipoprotein particle concentration | Large VLDL | 1.77 (1.36–2.31) | <0.001  | 1.67 (1.25–2.24) | <0.001  |
|                     | Medium VLDL           | 1.56 (1.20–2.03) | <0.001  | 1.48 (1.12–1.95) | <0.001  |
|                     | Small VLDL            | 2.34 (1.62–3.37) | <0.001  | 2.40 (1.57–3.68) | <0.001  |
|                     | Small LDL             | 1.70 (1.20–2.40) | 0.003   | 2.71 (1.52–4.82) | <0.001  |
|                     | Medium HDL            | 0.15 (0.05–0.49) | 0.002   | 0.22 (0.07–0.66) | 0.007   |
| Amino acids         | Alanine               | 0.33 (0.20–0.53) | <0.001  | 0.38 (0.24–0.60) | <0.001  |
|                     | Creatine phosphate    | 0.43 (0.22–0.84) | 0.01    | 0.36 (0.18–0.76) | 0.007   |
|                     | Creatine              | 0.34 (0.20–0.59) | <0.001  | 0.27 (0.14–0.51) | <0.001  |
|                     | Cysteine              | 0.35 (0.20–0.60) | <0.001  | 0.29 (0.15–0.55) | <0.001  |
|                     | Glutamine             | 0.32 (0.18–0.57) | <0.001  | 0.29 (0.15–0.53) | <0.001  |
|                     | N-acetylglutamine      | 0.28 (0.18–0.44) | <0.001  | 0.27 (0.16–0.44) | <0.001  |
|                     | Proline               | 0.34 (0.19–0.62) | <0.001  | 0.33 (0.18–0.61) | <0.001  |
|                     | Leucine               | 0.32 (0.20–0.51) | <0.001  | 0.37 (0.23–0.59) | <0.001  |
| Fatty acids         | CH2CH2CO              | 3.38 (2.07–5.52) | <0.001  | 3.03 (1.87–4.91) | <0.001  |
|                     | CH2N                 | 2.79 (1.69–4.60) | <0.001  | 2.77 (1.62–4.73) | <0.001  |
|                     | Isobutyrate           | 0.22 (0.13–0.37) | <0.001  | 0.27 (0.16–0.46) | <0.001  |
| Group                              | Metabolite       | RR (95% CI)          | p-value | Model 2     | p-value | RD (95% CI)          | p-value |
|-----------------------------------|------------------|----------------------|---------|-------------|---------|----------------------|---------|
| Fluid balance                     | Albumin          | 0.34 (0.20–0.58)     | < 0.001 | 0.26 (0.14–0.50) | < 0.001 | −50.89 (−84.27, −17.52) | 0.003   |
|                                   | Creatinine       | 0.65 (0.34–1.26)     | 0.21    | 0.56 (0.26–1.17) | 0.12    | −16.96 (−46.61, 12.68) | 0.26    |
| Energy metabolism                 | Citrate          | 0.30 (0.16–0.57)     | < 0.001 | 0.27 (0.14–0.55) | < 0.001 | −49.90 (−84.40, −15.40) | 0.005   |
|                                   | Pyruvate         | 0.32 (0.18–0.59)     | < 0.001 | 0.31 (0.16–0.58) | < 0.001 | −49.48 (−84.04, −14.92) | 0.005   |
| Ketone bodies                     | Acetate          | 0.28 (0.15–0.52)     | < 0.001 | 0.27 (0.15–0.51) | < 0.001 | −62.62 (−101.68, −23.55) | 0.002   |
|                                   | Acetone          | 3.19 (1.97–5.15)     | < 0.001 | 2.88 (1.84–4.51) | < 0.001 | 75.63 (32.20, 119.05) | < 0.001 |
| Products of bacterial co-         | 3-Hydroxybu-     | 0.36 (0.20–0.64)     | < 0.001 | 0.34 (0.18–0.63) | < 0.001 | −48.61 (−82.22, −13.00) | 0.007   |
| metabolism                        | tyrate           | 0.47 (0.23–0.93)     | 0.03    | 0.39 (0.18–0.85) | 0.02    | −31.46 (−63.24, 0.31) | 0.05    |
|                                  | Trimethylamines  | 0.29 (0.16–0.53)     | < 0.001 | 0.23 (0.12–0.45) | < 0.001 | −52.59 (−86.57, −18.61) | 0.002   |
|                                  | Phenylopropionate| 0.34 (0.21–0.54)     | < 0.001 | 0.39 (0.26–0.59) | < 0.001 | −70.33 (−112.40, −28.25) | 0.001   |
|                                  | O-phosphoethanol| 0.38 (0.20–0.72)     | 0.003   | 0.33 (0.17–0.65) | 0.002   | −42.53 (−77.86, −7.19) | 0.02    |

Abbreviations: RR rate ratio; RD rate difference; CI confidence interval. *n = 830

Model 1 was adjusted for age (years), sex (men, women) and education (< high school, > high school). Model 2 was model 1 additionally adjusted for prevalent hypertension (no, yes), total plasma cholesterol (mg/dL) and use of lipid lowering medication (no, yes).

Table 4  Difference in type 2 diabetes incidence per 10,000 person-years per 1-point HLS increase

| Adjustment models                                                                 | Difference in type 2 diabetes rates per 10,000 person-years (95% CI) | Percent explained, % (95% CI) |
|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------|-------------------------------|
| Age, sex, education, prevalent hypertension, total plasma cholesterol, use of lipid lowering medication (Reference Model) | −8.23 (−16.3, −0.13)                                                   | Reference                     |
| Reference model + lipoprotein subclasses                                          | −4.45 (−12.65, 3.75)                                                  | 45.9 (3.6, 238.7)             |
| Reference model + amino acids                                                     | −4.49 (−13.06, 4.08)                                                  | 45.4 (7.2, 274.0)             |
| Reference model + fatty acids                                                     | −6.38 (−15.00, 2.24)                                                  | 22.5 (−11.2, 164.1)           |
| Reference model + fluid balance                                                   | −6.12 (−14.58, 2.34)                                                  | 25.6 (4.4, 223.7)             |
| Reference model + energy                                                          | −5.20 (−13.93, 3.54)                                                  | 36.8 (0.3, 285.2)             |
| Reference model + products of bacterial co-metabolism                            | −5.10 (−13.82, 3.62)                                                  | 38.0 (2.8, 266.2)             |
| Reference model + O-phosphoethanolamine                                           | −6.24 (−14.79, 2.31)                                                  | 24.2 (2.9, 211.3)             |
| Reference model + phenylpropionate, and medium HDL and small LDL particle concentrations | −3.91 (−12.25, 4.44)                                                  | 52.5 (15.9, 384.3)            |

Abbreviations: CI confidence interval

* Aalen additive models with progressive degrees of adjustment; n = 830, 51 incident type 2 diabetes cases and 779 non-cases

* Relevant metabolites defined as showing a PIP > 20% in BKMR-P regression

* Bias-corrected and accelerated 95% confidence intervals from bootstrap based on 1000 resamplings as conducted by the boot R package
from the product of coefficient method (from Supplementary Table S10) was essentially similar to the originally estimated percent of the HLS-diabetes association explained by the 3 metabolites simultaneously entered as a group (Table 4).

**Discussion**

In this population-based cohort with a 14-year follow-up, the HLS, a composite healthy-lifestyle measure, was cross-sectionally associated to plasma metabolomic profiles mostly representing lipoprotein subclasses, amino acids, energy metabolism, fatty acids, products of bacterial co-metabolism and fluid balance metabolites. While most of these metabolites were individually associated with type 2 diabetes risk in single-metabolite models, phenylpropionate and medium HDL followed by small LDL particle concentrations largely drove the prospective association of jointly modelled metabolites with diabetes, and explained ~ 50% of avoided type 2 diabetes cases attributable to healthy lifestyle. Our results, thus, support that early metabolic changes related to lifestyle may have an impactful role in type 2 diabetes prevention.

The association of lifestyle and type 2 diabetes is widely known. The available evidence is based on several prospective studies of healthy lifestyle scores and incident type 2 diabetes [28, 29]; a meta-analysis of 14 prospective studies that evaluated the association between combined lifestyle factors and incident type 2 diabetes [3]; and a meta-analysis of randomized clinical trials that summarized the long-term effect of different combined lifestyle interventions in individuals at high risk of type 2 diabetes [30]. However, the contribution of plasma metabolites to explain the association of overall lifestyle and incident type 2 diabetes had not been evaluated before.

We observed a strong association of HLS with metabolites profiles reflecting several metabolic pathways. Scarce studies have previously evaluated the association between lifestyle —as a composite measure— with metabolomics measures. In the EPIC cohort, a modified healthy lifestyle index (diet, BMI, physical activity, lifetime alcohol, smoking, diabetes and hepatitis) was related to a serum metabolic signature composed of hexoses, glutamic acid, sphingomyelins and a phosphatidylcholine [8]. In our study, metabolites involved in related metabolic pathways, including several amino acids, as well as markers of energy metabolism, were consistently associated to healthy lifestyle adherence. Additionally, we identified other metabolites types, mainly lipoprotein subclasses; but also products from bacterial co-metabolism; fluid balance; fatty acids and O-phosphoethanolamine, which had not been previously investigated in relation to overall lifestyle.

Importantly, most of the identified HLS-related metabolites in our study were also prospectively associated with type 2 diabetes. Some components of the lipoprotein profile that were found to be positively associated to type 2 diabetes in our study, have been previously reported [specifically VLDL cholesterol [31], HDL cholesterol [10, 31, 32], VLDL triglycerides [31]; large and small VLDL [10] and small LDL [32]]. Similarly, components of the amino acids (e.g. alanine, creatine, glutamine, proline) [33] and the bacterial co-metabolism (phenylpropionate) [34, 35] groups, have been consistently associated to type 2 diabetes risk in other studies. However, the mechanisms that explain the associations between most of plasma metabolites measured in our study and type 2 diabetes remain largely unclear.

Evidence obtained from animal models shows that the exogenous administration of glutamine improves glucose tolerance [36], while the administration of creatine [37] or cysteine [38] decreases glycemia. Interestingly, this is the first study to find an association between plasma O-phosphoethanolamine levels with incident type 2 diabetes. In In-vitro studies, O-phosphoethanolamine up-stream precursor Sphingosine-1-Phosphate, counterbalanced insulin-resistance in peripheral tissues such as liver and muscle, and protected pancreatic beta cells from apoptosis [39]. Moreover, in a study among type 2 diabetes-free participants, fasting plasma insulin and insulin resistant measures have been positively correlated with O-phosphoethanolamine downstream product phosphatidylethanolamine [40]. Thus, this finding is consistent with the available evidence in favor of a biological role of sphingolipid metabolism on diabetes.

While the fact that the metabolite subgroups are correlated makes it difficult to separate the relative contribution of the individual subgroups, in BKMR-P analyses, which accommodate highly dimensional correlated variables simultaneously, phenylpropionate, and the medium HDL and small LDL particle concentrations drove most of the observed joint association of metabolites with diabetes. Microbial-related phenylpropionate is positively correlated with whole grain and fruit intake [41], dietary fiber and microbiome diversity [34], and although has been associated to incident type 2 diabetes [34, 35], their precise mechanism of action is unknown. However, it is hypothesized that its antioxidant properties could decrease insulin resistance [34]. Alternatively, type 2 diabetes is frequently preceded by a dyslipidemia characterized by hypertriglyceridemia with low HDL cholesterol levels and reduced LDL size [42], which is induced by an increased hepatic secretion of large VLDL particles that interact with the cholesteryl ester transfer protein and hepatic lipase [42, 43]. The progressive replacement of cholesteryl esters by triglycerides in the HDL particle
gradually generates smaller and denser particles [44]. Additional experimental research, however, is needed to further clarify the role of the specific lipoprotein subclasses concentrations on type 2 diabetes development.

The present study is not exempt of limitations. For instance, the fact that only individuals with suggestive evidence of altered non-fasting glucose levels underwent a second measurement in fasting condition allowed for analysis of diabetes status but not for glycaemia as a continuous measure, possibly a more powerful endpoint. Similarly, no information on insulin sensitivity or secretion was available, which could have provided additional insights relative to metabolic pathways in pre-diabetes. Moreover, the limited number of type 2 diabetes cases may not have enough power to detect interactions. The direction of the associations was, however, consistent in all the evaluated subgroups. Additionally, the HLS was derived mainly from self-reported information, thus non-differential miss-classification of the HLS components, which could attenuate the observed associations, cannot be ruled out. Alternatively, differential miss-classification of habits potentially related to social stigma such as alcohol intake may introduce some bias. Nonetheless, self-reported dietary information has been widely used on several other population cohorts. Importantly, the results from our sensitivity analysis support that biases introduced by alcohol are unlikely, although information on binge drinking pattern was unavailable. An additional limitation relates to the fact that metabolomic data was obtained using a targeted approach and only a predefined set of metabolites was available. Thus, we may have missed relevant metabolites. Nonetheless, in our data early lifestyle-related metabolic signatures widely explained the association between a healthy lifestyle and the subsequent occurrence of type 2 diabetes. This assertion is backed by study strengths such as the complex sampling design, which makes our study population representative of the general population from a Spanish region, the prospective study design, and the long follow-up.

Conclusions
In our population-based sample, we observed a strong, inverse, association of HLS with incident type 2 diabetes, which was substantially explained by differences in lifestyle-related plasma metabolites measured years before the type 2 diabetes clinical diagnosis. Our data support that lifestyle-related metabolic changes have a relevant biological role in type 2 diabetes development, and suggest that metabolomics can contribute to the early identification of individuals who could benefit from intensified lifestyle-related precision interventions for the type 2 diabetes prevention and control.

Abbreviations
HLS: Healthy lifestyle score; BMI: Body mass index; RR: Rate ratio; RD: Rate difference; CI: Confidence interval; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; BKMR-P: Bayesian kernel machine regression-probit; UHRRH: University hospital rio hortega; HbA1c: Hemoglobin type A; subfraction 1c (glycated hemoglobin); aMED: Alternate Mediterranean diet score; AHEI: Alternate healthy eating index; MET: Metabolic equivalent of task; NMR: Nuclear magnetic resonance; ppm: parts per million; VLDL: Very-low-density lipoprotein; FDR: False discovery rate; PIP: Posterior inclusion probability; IDL: Intermediate-density lipoprotein; MD: Mean difference; EPIC: European prospective investigation into cancer and nutrition cohort.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12966-021-01219-3.

Additional file 1. Additional findings that further support and/or give further detail to the main results.

Acknowledgements
Not applicable.

Authors’ contributions
M.D.V, M.T.P and M.S.P, formulated the study question and design. M.D.V, A.D.R and M.T.P performed the statistical analyses. All authors contributed to the acquisition and interpretation of the study results: M.D.V, D.M.S, M.T.P and M.S.P drafted/editied the manuscript. All authors contributed to the critical revision of the manuscript and approved the final version. M.S.P and M.T.P share primary responsibility for the final manuscript content and, as guarantors of this work, have access to the data.

Funding
This work was supported by the Strategic Action for Research in Health sciences [P110/0082, P113/01848, P114/00874, P116/01402, P111/00726, P116/609, P116/1512, P118/287, P119/319 and PI20/00896], the GUTMOM Project (JPI-A Healthy Diet for a Healthy Life INTIMIC-085, State Secretary of R+D+i PCIN-2017-117), the Cátedra de Epidemiología y Control del Riesgo Cardiovascular at UAM (M2002/4), the State Agency for Research (PID2019-108979GB-C21 and C22), the Valencia Government (GRUP03/101; PROMETEO/2009/029 and ACOMP/2013/039), the Castilla-Leon Government (GRS/279/A/08) and European Network of Excellence Ingenious Hypercare (EPSS-037093) from the European Commission, CIBER Fisiopatología Obesidad y Nutrición (CIBERON) (CIBER-02-08-2009, CB06/03 and CB12-03/0016). MSP holds a Ramón y Cajal contract (RYC-2018-025069-I) from the Ministry of Science, Innovation and Universities. MDV holds a “Predoctoral Training in Health Research” contract (F120/00162) from the Carlos III Health Institute. MGP and ADR received the support of a fellowship from “la Caixa” Foundation (ID 100001034, fellowship codes LCF/BQ/IN18/11660001, and LCF/BQ/DR19/11740016, respectively). PO received the support of a Sara Borrell contract from the Carlos III Health Institute (reference CD16/00255). The Strategic Action for Research in Health Sciences, CIBERON are initiatives from Carlos III Health Institute Madrid and co-funded by the European Social Fund “The ESF - investing in your future”. The State Agency for Research and Carlos III Health Institute belong to the Spanish Ministry of Science and Innovation. The funding bodies had no role in the study design, data collection and analysis, interpretation of results, manuscript preparation or in the decision to submit this manuscript for publication.

Availability of data and materials
The datasets analyzed during the current study are not publicly available since the steering committee and the participants did not approve unrestricted data sharing. However, data can be accessed upon a reasonable request.
Declarations

Ethics approval and consent to participate
The research protocol and each phase of the study were approved by the Ethics Committee of the University Hospital Rio Hortega (committee’s reference number, CEIC/12/01/03). All participants provided written informed consent.

Consent for publication
Not applicable.

Competing interests
N.A. is stock owner of Biosfer Teslab, the company that commercialize the lipoprotein profiling described in the present manuscript, and has a patent for lipoprotein profiling. All other authors declare that they have no competing interests.

Author details
1. Department of Preventive Medicine and Public Health, School of Medicine, Universitat Autonoma de Madrid, Instituto de Investigacion Sanitaria Hospital Universitario La Paz (IdiPaz), Madrid, Spain. 2. Department of Physiology, School of Medicine, University of Valencia, Valencia, Spain. 3. Institute for Biomedical Research Hospital Clinic de Valencia INCLIVA, Valencia, Spain. 4. Integrative Epidemiology Group, Department of Chronic Diseases Epidemiology, National Center for Epidemiology, Carlos III Health Institutes, Madrid, Spain. 5. Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, NY, USA. 6. Department of Statistics and Operations Research, University of Valencia, Valencia, Spain. 7. Department of Legal Medicine and Toxicology: School of Medicine, University of Granada, Granada, Spain. 8. Department of Chronic Diseases Epidemiology, National Center for Epidemiology, Carlos III Health Institute, Monforte de Lemos, S, 28029 Madrid, Spain. 9. CIBERESP (CIBER of Epidemiology and Public Health), Madrid, Spain. 10. IMDEA-Food Institute, CEI UAM-4-CISC, Madrid, Spain. 11. Biosfer Teslab, Av. Universitat, 143204 Reus, Spain. 12. Department of Basic Medical Sciences, University Rovira i Virgili, Reus, Spain. 13. CIBERDEM (CIBER of Diabetes and Metabolic Diseases), Madrid, Spain. 14. Department of Internal Medicine, University Hospital Rio Hortega, Valladolid, Spain. 15. CIBERFES (CIBER of Frailty and Healthy Aging), Madrid, Spain. 16. Department of Pathology, University of Valencia, Av. Blasco Ibáñez, 15, 46010 Valencia, Spain. 17. Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Received: 12 March 2021   Accepted: 20 October 2021

Published online: 27 January 2022

References

1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract 2019;157:10843. https://doi.org/10.1016/j.diabres.2019.10843.
2. Lippi G, Griffi JL. Metabolomics applied to diabetes—lessons from human population studies. Int J Biochem Cell Biol 2017;93:136–147. https://doi.org/10.1016/j.biocel.2017.10.011.
3. Zhang Y, Pan XF, Chen J, Xia L, Cao A, Zhang Y, et al. Combined lifestyle factors and risk of incident type 2 diabetes and prognosis among individuals with type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies. Diabetologia 2020;63:21–33. https://doi.org/10.1007/s00125-019-04985-9.
4. Mozaffarian D, Kamineni A, Mozaffarian D, Kamineni A, Campos H, Murabito JM, et al. Metabolic signature of healthy lifestyle and its relation with risk of hepatocellular carcinoma in a large European cohort. Am J Clin Nutr 2018;11:117–126. https://doi.org/10.1093/ajcn/nqy074.
5. Playdon MC, Moore SC, Derkach A, Reddy J, Subar AF, Sampson JN, et al. Identifying biomarkers of dietary patterns by using metabolomics. Am J Clin Nutr 2017;105:450–465. https://doi.org/10.3945/ajcn.116.144501.
6. Guasch-Ferré M, Hruby A, Toledo E, Clích CB, Martinez-González MA, Salas-Salvadó J, et al. Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis. Diabetes Care 2016;39:833–846. https://doi.org/10.2337/dctd-15-2325.
7. Wurtz P, Cook S, Wang Q, Tianien M, Tynkkynen T, Kangas AJ, et al. Metabolic profiling of alcohol consumption in 97/87 young adults. Int J Epidemiol 2016;45:1493–1506. https://doi.org/10.1093/ije/dyw175.
8. Li J, Yu C, Guo Y, Bian Z, Yang L, Chen Y, et al. Adherence to a healthy lifestyle and the risk of type 2 diabetes in Chinese adults. Int J Epidemiol 2017;46:1410–1420. https://doi.org/10.1093/ije/dyx074.
9. Klein MS, Shearer J. Metabolomics and type 2 diabetes: translating basic research into clinical application. J Diabetes Res 2016;2016:3898502. https://doi.org/10.1155/2016/3898502.
25. Griswold MG, Fullman N, Hawley C, Arian N, Zimmes SRM, Tymeson HD, et al. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet 2018;392:1015-1035. https://doi.org/10.1016/S0140-6736(18)31310-2.

26. Lange T, Hansen JV. Direct and indirect effects in a survival context. Epidemiology 2011;22:575-581. https://doi.org/10.1097/EDE.b013e11821c680c.

27. Huang YT, Yang HL. Causal mediation analysis of survival outcome with multiple mediators. Epidemiology 2017;28:370-378. https://doi.org/10.1097/EDE.0000000000000651.

28. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon GD, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001;345:790-797. https://doi.org/10.1056/NEJMoa010492.

29. Ruiz-Estigarribia L, Martinez-Gonzalez MA, Diaz-Gutierrez J, Sayon-Orea C, Basterra-Gortari FJ, Bes-Rastrollo M. Lifestyle behavior and the risk of type 2 diabetes in the Seguimiento Universidad de Navarra (SUN) cohort. Nutr Metab Cardiovasc Dis 2020;30:1355-1364. https://doi.org/10.1016/j.numecd.2020.04.006.

30. Uusitupa M, Khan TA, Viguiliouk E, Kahleova H, Rivellese AA, Hermansen K, et al. Prevention of type 2 diabetes by lifestyle changes: a systematic review and meta-analysis. Nutrients 2019;11:2611. https://doi.org/10.3390/nu1112611.

31. Aholu-Avi A, Mustelin L, Kalimeri M, Kettunen J, Jokelainen J, Auvinen J, et al. Circulating metabolites and the risk of type 2 diabetes: a prospective study of 11,896 young adults from four Finnish cohorts. Diabetologia 2019;62:2298-2309. https://doi.org/10.1007/s00125-019-05001-w.

32. MacKey RH, Mora S, Bertoni AG, Wassel CL, Carnethon MR, Sibley CT, et al. Lipoprotein particles and incident type 2 diabetes in the multi-ethnic study of atherosclerosis. Diabetes Care 2015;38:628-636. https://doi.org/10.2337/dc14-0645.

33. Liu X, Gao J, Chen J, Wang Z, Shi Q, Man H, et al. Identification of metabolic biomarkers in patients with type 2 diabetic coronary heart diseases based on metabolomic approach. Sci Rep 2016;6:1-13. https://doi.org/10.1038/srep30785.

34. Menni C, Zhu J, Le Roy CI, Mompeo O, Young K, Rebhdz CM, et al. Serum metabolites reflecting gut microbiome alpha diversity predict type 2 diabetes. Gut Microbes 2020;11:1632-1642. https://doi.org/10.1080/19499097.2020.1778261.

35. Vangipurapu J, Fernandes Silva L, Kuulasmaa T, Smith U, Laakso M. Microbiota-related metabolites and the risk of type 2 diabetes. Diabetes Care 2020;43:1319-1325. https://doi.org/10.2337/dc19-2533.

36. Cheng S, Rhee EP, Lanson MG, Lewis GD, McBride EL, Shen D, et al. Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation 2012;125:2222-2231. https://doi.org/10.1161/CIRCULATIONAHA.111.067827.

37. Rahmani A, Asadollahi K, Soleimannejad K, Khalighi Z, Mohsenzadeh Y, Hemati R, et al. The effects of Creatine monohydrate on permeability of coronary artery endothelium and level of blood lipoprotein in diabetic rats. Ann Clin Lab Sci. 2016;46:495-501.

38. Jain SK, Velusamy T, Croaz JL, Rains JL, Bull R. L-cysteine supplementation lowers blood glucose, glycated hemoglobin, CRP, MCP-1, and oxidative stress and inhibits NF-kB activation in the livers of Zucker diabetic rats. Free Radic Biol Med 2009;46:1633-1638. https://doi.org/10.1016/j.freeradbiomed.2009.03.014.

39. Guittion J, Bandiet CL, Mariko ML, Tan-Chen S, Bourron O, Benomar Y, et al. Sphingosine-1-phosphate metabolism in the regulation of obesity/type 2 diabetes. Cells 2020;9:1682. https://doi.org/10.3390/cells9101682.

40. Younesi M, Quilliot D, Al-Makdissy N, Delbachian I, Drouin P, Donner M, et al. Erythrocyte membrane phospholipid composition is related to hyperinsulinemia in obese non-diabetic women: effects of weight loss. Metabolism 2002;51:1261-1268. https://doi.org/10.1016/S0026-0495(02)00046-3.

41. Pallister T, Jackson MA, Martin TC, Zierer J, Jennings A, Mohney RP, et al. Hippurate as a metabolomic marker of gut microbiome diversity: modulation by diet and relationship to metabolic syndrome. Sci Rep 2017;7:13670. https://doi.org/10.1038/s41598-017-13722-4.

42. Adiels M, Olofsson S-C, Taskinen M-R, Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidaemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:1225-1236. https://doi.org/10.1161/ATVBAHA.107.160192.

43. Sparks JD, Sparks CE, Adeli K. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2012;32:2104-2112. https://doi.org/10.1161/ATVBAHA.111.241463.

44. Lewis GF, Radin DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005;96:1221-1232. https://doi.org/10.1161/01.RES.0000170946.56981.5c.